Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study have?
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study has 405 citations in the OpenAlex counts ScholarIQ stores.
When was Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study published?
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study has 2018 year in the ScholarIQ index.
What is the open-access status of Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study?
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study has green oa status in the ScholarIQ index.
What is the DOI of Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study?
The DOI for Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study is on the source record.
What is the PMID of Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study?
The PMID for Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study is on the source record.
What is the OpenAlex record for Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study?
The OpenAlex for Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study is on the source record.